AU · rank #4 · 2026-09-10
NUTX
NASDAQ · $1.31B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.809 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$4.84 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 5 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.172 |
| Analyst upside Consensus target $276.00 | +39.6% |
| Momentum acceleration 3-month minus 12-month momentum. | +2.53% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.67 |
| Gross margin TTM | +54.5% |
| 52w high | $204.00 |
| Market cap (USD) | $1.31B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Nutex Health operates a network of physician-led micro-hospitals and outpatient departments alongside a Population Health Management division running risk-bearing provider networks.
Rationale
Unanimous analyst revision agreement and high price target upside are strongly validated by explosive FY 2025 financial growth, including an 82.4% revenue surge and an 89.3% earnings surprise.
Material risks
- 1High dependence on out-of-network billing and the No Surprises Act's arbitration mechanism leaves revenue highly vulnerable to adverse regulatory changes or insurance payer pushback.
- 2Recent restatements of quarterly financials and rescheduled earnings indicate persistent accounting and internal control complexity that could erode market trust.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.